According to previous results, oral and intraperitoneal administration of sitagliptin at high doses, exerted a limiting effect on infarct size and triggered pro-survival signaling cascades (PI3K-Akt and ERK1/2) by GLP-1 upregulation, as responses to ischemia reperfusion (IR) injury [27]. This evidence concerns the gene MAPK3 and ischemia.